Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions designed to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite evidence surrounding the efficacy of regimens with novel proteasome inhibitors, immunomodulatory drugs, antibodies, targeted therapies, and cell therapies across multiple myeloma (MM) treatment settings, including smoldering MM, newly diagnosed MM, and relapsed/refractory MM, Se

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treat

Go online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon completion of this accredited CE activity, participants should be better able to: Identify the clinical signs of AML, relevant prognostic factors, and patient- or disease-related features that influence treatment selection, Discuss efficacy and safety evidence surrounding novel cytotoxic, targeted, and epigenetic therapies for AML, Develop educational strategies for patients with AML related to therapeutic expectations, adherence, safety considerations, sequential treatments, and differences among novel agent classes, Manage d

Go online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the global disease burden, etiopathogenesis, risk factors, and stratification scores for cancer-associated VTE using established diagnostic tools, Review safety & efficacy evidence, clinical trial data, and practice guidelines for currently available treatment options for managing cancer-associated VTE, Employ guideline-concordant, evidence-based care and shared decision-making strategies including multidisciplinary and interprofessional collaboration for prevention and treatment of cancer-associated VTE in routine clinica